Research and drug development regarding CAR T-cell therapies has been rapidly progressing and expanding over the past few years. In order to attack the ‘antigen loss’ problem, researchers are looking into potential other antigen targets that can be used in combination with CD19 CAR T-cells as a form of treatment ‘cocktail’. Researchers have also been looking into application of CAR T-cell therapy for patients with blood cancers and solid tumors. Therapies regarding solid tumors have proven difficult due to the microenvironment of the tumor that makes immune response extremely difficult.
Recent comments